Ipamorelin vs hexarelin: how the two secretagogues differ

Last updated 2026-07-24

What is the actual difference between ipamorelin and hexarelin?

Both peptides are growth hormone releasing peptides (GHRPs) that act on the ghrelin receptor (GHS-R1a) to stimulate pituitary GH release. The core difference is selectivity. Ipamorelin was developed specifically to hit the GH pathway without dragging cortisol, prolactin, or ACTH along with it, a property confirmed in the original 1998 characterization published in the European Journal of Endocrinology, which describes it as "the first selective growth hormone secretagogue" ^[1]. Hexarelin, an older hexapeptide, is a stronger GH secretagogue on a per-dose basis but it also stimulates cortisol and prolactin release, and it has more affinity for cardiac and other non-pituitary tissue. Think of it as a tradeoff between raw potency and cleanliness. Hexarelin pulls the lever harder. Ipamorelin pulls a narrower, more specific lever. For someone trying to avoid the puffy, cortisol-driven water retention or the prolactin-related side effects that older GHRPs are known for in anecdotal reports, that selectivity matters. Medicinal chemistry work on ipamorelin's structure-activity relationship shows the pentapeptide's specific residue substitutions were engineered to reduce ACTH and cortisol co-release compared to earlier GHRP-6-family compounds ^[2][3].

How do ipamorelin and hexarelin compare in mechanism of action?

Both are ghrelin mimetics binding the same GHS-R1a receptor on pituitary somatotrophs, which is the mechanism class covered in a 2020 review on ghrelin mimetics and pain modulation ^[4]. Downstream, both trigger a pulse of GH secretion, but the pharmacodynamic profile differs. Ipamorelin's pharmacokinetic-pharmacodynamic modeling in human volunteers found a dose-dependent GH pulse without meaningfully raising cortisol, insulin, or glucose at studied doses, a key point in the 1999 Pharmaceutical Research modeling study ^[5]. Nasal absorption data from the same era found peptidyl secretagogues including ipamorelin have low oral and nasal bioavailability, which is part of why injectable delivery dominates clinical and research use ^[6]. Hexarelin's broader receptor engagement is what gives it stronger cortisol and prolactin co-release, plus effects on cardiac tissue that have made it a subject of cardioprotection research separate from its GH activity. That's a mechanism ipamorelin does not meaningfully share, since ipamorelin was built to avoid exactly that kind of off-target signaling.

Which one is more potent for raising GH levels?

Hexarelin is generally considered the more potent GH secretagogue of the two on a milligram basis, largely because it isn't filtering its receptor engagement the way ipamorelin does. But potency isn't the same as usefulness. A 1998 medicinal chemistry paper describing novel orally active growth hormone secretagogues placed ipamorelin's development in the context of a broader search for compounds with a favorable selectivity profile, more than raw GH output ^[2]. In practice, the potency gap between the two doesn't translate into a straightforward "hexarelin works better" conclusion, because higher potency at a non-selective receptor also means more of the side-effect baggage. If your goal is a GH pulse with the fewest downstream hormonal disturbances, selectivity usually wins over brute-force potency. If you're chasing the single biggest acute GH spike regardless of what else moves with it, hexarelin will likely produce a bigger number.

How do their side effect profiles compare?

This is where the two drugs diverge most clearly. Ipamorelin's defining trait in the literature is that it does not meaningfully raise cortisol, aldosterone, or prolactin at the doses studied, which is the specific finding the 1998 European Journal of Endocrinology paper reports when it names ipamorelin the first selective secretagogue ^[1]. Hexarelin, by contrast, is known to raise both cortisol and prolactin alongside GH, an effect tied to its broader receptor binding. Neither peptide is FDA-approved, and neither has the kind of large-scale human safety trial data you'd want before calling either one "safe" in a blanket sense. A 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal and athletic use frames both compounds within a category where efficacy and safety data remain limited relative to approved drugs ^[7]. A companion 2026 review in the American Journal of Sports Medicine, written as a primer for orthopaedic and sports medicine physicians, makes a similar point about injectable peptides broadly: promising preclinical signal, thin clinical trial base ^[8]. For a full rundown on what ipamorelin's reported side effects look like across the available literature, see ipamorelin side effects.

Do ipamorelin and hexarelin affect appetite differently?

Both act on the ghrelin receptor, which is the same receptor that drives ghrelin's natural appetite-stimulating effect, so some appetite stimulation is plausible for both. The clearest data here actually comes from an unusual source: a 2024 study in ferrets found that both anamorelin and ipamorelin blunted cisplatin-induced weight loss, with anamorelin also showing an anti-emetic effect through a central mechanism ^[9]. That's an animal model in an oncology-adjacent context, not a bodybuilding population, so treat it as mechanistic support rather than a green light for appetite management in healthy adults. Hexarelin's appetite effects haven't been characterized nearly as well in the specific literature provided here, though its shared receptor mechanism suggests a similar directional effect is biologically plausible. Neither compound has trial data in healthy humans establishing appetite change as a primary, reliable outcome.

What does the research actually say about each peptide's evidence base?

Ipamorelin has the deeper research trail of the two, dating back to its 1998 characterization ^[1] and extending through rat studies on bone growth ^[10], bone mineral content ^[11], glucocorticoid-induced bone loss ^[12], and even a randomized controlled trial in humans for postoperative ileus after bowel resection ^[13]. That ileus trial is worth naming specifically: it's a real, controlled, proof-of-concept study in surgical patients, not a mechanism paper in rodents, which puts it in a different evidentiary category from most of the rest of the ipamorelin literature. Hexarelin's evidence in the sources compiled here is thinner and mostly folded into broader secretagogue-class discussions rather than standing on its own dedicated trials. Neither peptide has gone through the FDA approval pathway, and you won't find either one in the Drugs@FDA database of approved drug products [FDA Drugs@FDA database]. A useful frame from the orthopaedics literature: a 2026 JAAOS Global Research & Reviews paper on therapeutic peptides in orthopaedics discusses applications, challenges, and future directions for this drug class broadly, underscoring that the field is still working out which peptides clear a real evidentiary bar and which are riding on preclinical promise ^[14].

Table: ipamorelin vs hexarelin at a glance

Why does selectivity matter if both raise GH?

Selectivity matters because GH isn't released in isolation from the rest of the endocrine system, and a secretagogue that also cranks cortisol or prolactin is asking your body to deal with more than one hormonal shift at once. Chronic cortisol elevation is linked to appetite changes, mood effects, and interference with the very tissue repair and lean mass gains someone might be chasing with a GH secretagogue in the first place. A 2009 study on GH and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats found that GH secretagogue treatment influenced protein metabolism in a steroid-exposed model, suggesting the interaction between GH pathway activation and glucocorticoid status is a real physiological variable worth paying attention to ^[15]. That's exactly the kind of interaction that gets messier when your secretagogue is also independently pushing cortisol up, which is the hexarelin pattern more than the ipamorelin one. There's also a separate finding worth knowing: GH secretagogues can stimulate adiposity through a GH-independent mechanism, according to a 2001 paper in Biochemical and Biophysical Research Communications . That means "more selective for GH" doesn't automatically mean "zero effect on fat tissue through some other pathway." It's a reminder that receptor selectivity narrows some risks without eliminating every downstream question.

How do dosing and administration compare?

Ipamorelin dosing in the studied literature is typically injectable, subcutaneous, and given in the microgram range, timed around meals or bedtime to align with the body's natural GH pulsatility. The Pharmaceutical Research modeling paper models exactly this kind of dose-response relationship in human volunteers ^[5], and separate metabolism work has traced how these peptides break down after administration, which matters for understanding half-life and dosing frequency ^[16]. Hexarelin dosing protocols in circulation, mostly anecdotal or research-context rather than clinical, tend to describe similar micro-dosing patterns but the drug's stronger cortisol and prolactin co-release is often cited as the reason some research users prefer to cycle it more conservatively or avoid daily use. Neither peptide has an FDA-approved label, so there is no official dosing chart for either one. Anything you see framed as a "standard protocol" for either peptide traces back to compounding pharmacy guidance, published pharmacokinetic studies in small volunteer cohorts, or forum-level extrapolation, not an approved package insert. If you want the detailed numbers behind how ipamorelin doses are typically structured in practice, see ipamorelin dosage, and if you're stacking it with CJC-1295, the cjc-1295 ipamorelin dosage calculator and reconstitute cjc ipamorelin guide walk through reconstitution and volume math.

Is either peptide FDA-approved, and how are they actually sourced?

No. Neither ipamorelin nor hexarelin is an FDA-approved drug product; you won't find either in the Drugs@FDA database [FDA Drugs@FDA database]. Both exist in the U.S. market almost entirely through compounding pharmacies operating under the 503A framework, which governs which bulk drug substances a compounding pharmacy can legally use, laid out in 21 CFR 216.23 [503A Bulks List] and the parallel 503B outsourcing facility list in 21 CFR 216.24 [503B Bulks List]. The statutory basis for pharmacy compounding itself sits in 21 U.S.C. 353a [21 U.S.C. 353a]. FDA maintains a running list of bulk substances nominated for use in compounding, which is where new peptides get evaluated for inclusion or exclusion from legitimate compounding practice [FDA bulk drug substances nominated list]. This matters practically: a peptide's regulatory status under this framework determines whether a licensed U.S. compounding pharmacy can legally prepare it at all, separate from any question of whether the science supports its use. There's also a real quality-control problem worth naming directly. A 2018 analysis of new growth-promoting black market products found meaningful discrepancies between labeled and actual content in unregulated peptide products sold outside licensed pharmacy channels ^[17]. That's the practical argument for sourcing through a provider-reviewed, pharmacy-fulfilled route rather than an unregulated seller, regardless of which secretagogue you're considering. Ipamorelin Co works with providers who route orders through a licensed compounding pharmacy partner, and the product dispensed is a tesamorelin/ipamorelin blend, not a standalone ipamorelin vial. There is no legitimate standalone ipamorelin SKU in that model. For details on how that process works, see buy ipamorelin.

Can you combine ipamorelin or hexarelin with CJC-1295?

Combining a GHRP like ipamorelin or hexarelin with a GHRH analog like CJC-1295 is a common pairing in the research and compounding literature, on the logic that the two act on different receptors (ghrelin receptor versus GHRH receptor) and can produce an additive GH pulse. Ipamorelin is the GHRP more commonly discussed alongside CJC-1295 in compounding pharmacy protocols; the reasoning is that ipamorelin's selectivity keeps the stack from also amplifying cortisol on top of whatever GH pulse the pair produces. There isn't a dedicated human trial in the sources reviewed here testing the ipamorelin/CJC-1295 combination specifically, or the hexarelin/CJC-1295 combination, head to head. Most of what circulates about stack ratios and timing comes from compounding pharmacy dosing guidance and forum protocol-sharing rather than published trials, so treat specific ratio claims as practice-based extrapolation, not settled pharmacology. If you want the mechanics of how that pairing is typically dosed, the cjc-1295 ipamorelin dosage calculator walks through it.

What does the evidence say about long-term or aging-related use?

A 2026 Frontiers in Aging review on therapeutic peptides in gerontology discusses mechanisms and applications of peptides, including GH secretagogues, in the context of healthy aging research, which signals real academic interest in this space beyond bodybuilding circles ^[18]. Separately, a 2020 Translational Andrology and Urology paper looked at GH secretagogues specifically in the context of body composition management in hypogonadal males, going "beyond the androgen receptor" as a treatment angle ^[19]. None of this amounts to long-term safety data for daily, multi-year use of ipamorelin or hexarelin in healthy adults. The aging and hypogonadism literature explores a rationale and mechanism, not a track record. A 2026 International Journal of Molecular Sciences review on therapeutic peptides in aesthetic, metabolic, and endocrine conditions covers safety and clinical application questions across this peptide class broadly, which is a useful frame: the field is actively mapping out where the evidence is solid and where it's still speculative ^[20].

Bottom line: which should you actually consider?

If you're weighing the two on the evidence compiled here, ipamorelin has the better-characterized selectivity profile, a real human RCT in a surgical context ^[13], and decades of mechanistic rat and rodent data behind it going back to 1998 ^[1]. Hexarelin brings more raw potency but drags cortisol and prolactin along with it, which is the tradeoff most people trying to avoid unwanted side effects will want to think hard about. Neither is FDA-approved. Neither has the kind of large human safety trial base you'd want before calling it routine. If you're going to use either, the sourcing question matters as much as the peptide choice: a 2018 analysis of unregulated black market growth-promoting products found real content discrepancies in that space ^[17], which is exactly the risk a provider-reviewed, pharmacy-fulfilled route is built to avoid. Start with the mechanism and dosing fundamentals at ipamorelin before deciding what, if anything, makes sense for your situation.

Frequently asked questions

Is ipamorelin stronger than hexarelin?

No, hexarelin is generally considered the more potent GH secretagogue per dose. Ipamorelin was designed for selectivity rather than maximum potency, meaning it triggers GH release with minimal cortisol or prolactin co-release, while hexarelin's stronger effect comes with less selective receptor engagement ^[1].

Does ipamorelin raise cortisol like hexarelin does?

No. Ipamorelin's defining trait in the original 1998 characterization is that it does not meaningfully raise cortisol, aldosterone, or prolactin at studied doses, unlike hexarelin, which is known to co-release both cortisol and prolactin alongside GH ^[1].

Is hexarelin FDA-approved?

No. Neither hexarelin nor ipamorelin is FDA-approved. Both are absent from the Drugs@FDA database of approved drug products, and both exist in the U.S. market only through compounding pharmacies operating under the 503A bulk substance framework in 21 CFR 216.23.

Can you buy hexarelin or ipamorelin as a standalone product?

Ipamorelin is not available as a standalone SKU through legitimate provider-reviewed channels; it is dispensed as part of a tesamorelin/ipamorelin blend through a licensed compounding pharmacy. Sourcing either peptide from unregulated sellers carries real quality-control risk, documented in a 2018 analysis of black market growth-promoting products ^[17].

Which has better human trial data, ipamorelin or hexarelin?

Ipamorelin has a randomized, controlled proof-of-concept trial in bowel resection patients for postoperative ileus ^[15], plus decades of rodent mechanism studies. The sources reviewed here don't show an equivalent dedicated human RCT for hexarelin, though that doesn't rule out data existing elsewhere in the broader literature.

Do ipamorelin and hexarelin affect appetite the same way?

Both act on the ghrelin receptor, which naturally drives appetite, so some stimulation is plausible for both. A 2024 ferret study found ipamorelin blunted cisplatin-induced weight loss, similar to anamorelin ^[8]. Hexarelin's appetite effects are not well characterized in dedicated human studies within the sources reviewed.

Why was ipamorelin developed if GHRP-6 and hexarelin already existed?

Ipamorelin was developed specifically to solve the selectivity problem older GHRPs had. The 1998 European Journal of Endocrinology paper names it the first selective growth hormone secretagogue, meaning it stimulates GH without the cortisol and prolactin co-release seen with earlier peptides like GHRP-6 and hexarelin ^[1].

Can ipamorelin and hexarelin be stacked with CJC-1295?

Both are discussed in compounding literature as pairing candidates with CJC-1295, a GHRH analog acting on a different receptor. Ipamorelin is the more commonly used pairing due to its selectivity. No dedicated human trial in the reviewed sources tests either combination head to head; protocols are largely practice-based.

Does hexarelin have cardiac effects that ipamorelin doesn't?

Hexarelin's broader receptor engagement includes activity in cardiac tissue that has made it a separate subject of cardioprotection research, a property not attributed to ipamorelin in the sources reviewed here, which describe ipamorelin as selective for the GH pathway specifically ^[1].

Is there a standard dosage difference between the two peptides?

There's no FDA-approved dosing chart for either. Published human pharmacokinetic modeling for ipamorelin used microgram-range subcutaneous doses in volunteer studies ^[13]. Hexarelin protocols circulating in compounding and research contexts describe similar micro-dosing but often with more conservative frequency due to cortisol and prolactin co-release.

What's the biggest practical risk difference between the two?

The main practical difference is side effect load from non-selective receptor engagement: hexarelin's cortisol and prolactin co-release versus ipamorelin's more targeted GH effect. Sourcing risk applies equally to both, since unregulated black market peptide products have documented content discrepancies ^[17].

Do either of these peptides help with tissue repair or ileus recovery?

Ipamorelin has direct evidence here: a randomized controlled trial found it useful as a proof-of-concept treatment for postoperative ileus after bowel resection ^[15], with supporting rodent gastric dysmotility data ^[19][20]. Hexarelin doesn't have an equivalent dedicated trial in the sources reviewed.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin is characterized as the first selective growth hormone secretagogue, sparing cortisol and prolactin unlike older GHRPs like hexarelin
2. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Reviews applications, challenges, and future directions for therapeutic peptides including GH secretagogues in orthopaedics
3. American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for orthopaedic and sports medicine physicians on injectable peptide therapy evidence and clinical use
4. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
5. Translational Andrology and Urology, 2020 (PMID 32257855): Discusses GH secretagogues for body composition management in hypogonadal males beyond androgen receptor mechanisms
6. Frontiers in Aging, 2026 (PMID 42021992): Reviews mechanisms and applications of therapeutic peptides including GH secretagogues for healthy aging
7. International Journal of Molecular Sciences, 2026 (PMID 42123471): Reviews effects, safety, and clinical applications of therapeutic peptides in aesthetic, metabolic, and endocrine conditions
8. Physiology & Behavior, 2024 (PMID 39043357): Ipamorelin and anamorelin inhibited cisplatin-induced weight loss in ferrets, with anamorelin also showing central anti-emetic effect
9. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Describes ghrelin mimetics' mechanism of action via the ghrelin receptor GHS-R1a and effects on nociception
10. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes development of novel orally active growth hormone secretagogues including selectivity considerations
11. Pharmaceutical Research, 1999 (PMID 10496658): Pharmacokinetic-pharmacodynamic modeling of ipamorelin's dose-dependent GH response in human volunteers
12. Growth Hormone & IGF Research, 2009 (PMID 19231263): GH secretagogue treatment affects nitrogen balance and urea synthesis in steroid-treated rats
13. International Journal of Colorectal Disease, 2014 (PMID 25331030): Randomized controlled proof-of-concept trial of ipamorelin for postoperative ileus in bowel resection patients
14. Analytical Chemistry, 2012 (PMID 23101768): Characterizes metabolism pathways of growth hormone releasing peptides including ipamorelin
15. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis found content discrepancies in new growth-promoting black market products
16. Xenobiotica, 1998 (PMID 9879640): Peptidyl GH secretagogues including ipamorelin have low oral and nasal bioavailability, favoring injectable delivery
17. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Ipamorelin improved gastric dysmotility in a rodent model of postoperative ileus
18. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decrease in bone formation in adult rats
19. The Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increased bone mineral content in adult female rats
20. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Describes structure-activity relationships behind a series of potent GH-releasing peptides derived from ipamorelin
21. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): GH secretagogues can stimulate adiposity through a GH-independent mechanism
22. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substances list governing what compounding pharmacies may legally use under section 503A
23. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances list for 503B outsourcing facilities
24. Cornell Law School, 21 U.S.C. 353a: Establishes the statutory basis for pharmacy compounding in the United States
25. FDA, bulk drug substances nominated for use in compounding: FDA maintains a current list of bulk substances nominated for evaluation for use in compounding
26. Drugs@FDA database: Neither ipamorelin nor hexarelin appears in the FDA's database of approved drug products